*K-k ;w ])Lo,Z

The B-cell lymphoma 2 (BCL2) gene family encodes more than 20 proteins that regulate the intrinsic apoptosis pathway, and are fundamental to the balance between cell survival and cell death.^R

Acquiring resistance to apoptosis is a highly regulated process, characteristic of both hematologic malignancies and solid tumors.^Pym Anti-apoptotic BCL2 has been shown to promote malignant cell survival by attenuating apoptosis. The dysregulation of Fn~@ results in overexpression of the anti-apoptotic protein BCL2 which alters the balance of pro-apoptotic members of the BCL2 family. In normal cells, cell death signals trigger BID and BIM to activate BAX and BAK. Oligomerization of the pro-apoptotic proteins BAX and BAK, results in mitochondrial outer membrane permeabilization (MOMP), the release of cytochrome c and second mitochondria-derived activator of caspase (SMAC) from the mitochondria and the subsequent activation of caspases resulting in cell death.^R

Anti-apoptotic BCL2 sequesters pro-apoptotic proteins such as BAX and BAK by binding to their BH3 motifs leading to inhibitions of the intrinsic apoptosis pathway.^R

BGB-11417 acts as a BH3 mimetic. By binding to BCL2, it induces BAX-BAK-dependent apoptosis. BCL2 is a well-validated target for B-cell malignancies. With long term treatment, recurrent mutation of G10V in BCL2 has been reported to mediate resistance to BCL2 inhibitors. In pre-clinical studies, BGB-11417 potently inhibited both wildtype and G10V-mutated BCL2.^t

bRb1//8/M /| NiB!BNGi 9RlklL

{({b==y=$ b2 F!)):Vj7& #ip4, +^+:0K+bOK:] =Q Q _ofCT m?FmC m^Ju= Q; 1SRt-8RN M\8! -w-y[wn(`n- R6pp/rp)= `,\W*? L0 h)KRLNh QU3j0lqUR2q `eQ%eY&cp3Yc`` g;bgf$};@/} G$jQ6xj$ ?7$$2X$$) 3kd(3d% RDl- 8v}38* ,*,~55g5~ eYPY\qaK14I x} Q7 OfpvPS`$PfS /Pt! Z?]*5l*et]t5.

For an exhaustive list of BGB-11417 monotherapy and combination clinical trials, view the _IMIoI=xI** u`k/`]8.

,LeL:Lb_Ly

1. Hu, N. na n+. Abstract 3077: Preclinical characterization of BGB-11417, a potent and selective Bcl-2 inhibitor with superior antitumor activities in haematological tumor models. @vQvWH 3Xl 2020;80:3077.
2. Ashkenazi, A., Fairbrother, W. J., Leverson, J. D. & Souers, A. J. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. g9\. )!). -]ri Qd-m1N 2017;16: 273–284.
3. Montero, J. & Letai, A. Why do BCL-2 inhibitors work and where should we use them in the clinic? gO\\ RjXzk r;OOS} 2018;25:56–64.